PTC/SB/08s (08-03.)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through DIFFICORE CMS total coats

U.S. Plettel and Tribademach Chies; U.S. DEPARTMENT OF COMMENCE

U.S. Plettel and Tribademach Chies; U.S. DEPARTMENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a visid OMS control number.

			Application Number									
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date								
				First Named Inventor Filip			po Ramin					
				Art Un	Art Unit							
(Not for submission under 37 CFR 1.99)				Examiner Name								
				Attorn	ey Doc	ket Numb	er	06UVB006				
					U.S.I	PATENTS				Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D		eited Desument		Releva	es,Columns,Lines where evant Passages or Relevant rres Appear			
	1	6094306		2000-07	2000-07-25 Jain			Abstract				
If you wis	h to a	dd additional U.S. Pater	nt citation	n inform	ation pl	ease click	the A	dd button.		Add		
			U.S.P	ATENT.	APPLIC	CATION P	UBLI	CATIONS		Remove		
Examiner Initial*					Publication Name of Patentee or Applicant Releva			s,Columns,Lines where ant Passages or Relevant es Appear				
	1											
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n informati	on pl	ease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOC	UME	NTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	on	upplicant of cited			or Relevant	
	1	0978617	EP			2002-02-0	19	Pitscheider et al.		Paragraph 0019	s 0011,	
	2	1273752	ΕP			2003-01-0	18	Schwoerer Haus K		Paragraph Figures	0016.	
If you wish to add additional Foreign Patent Document citation information please click the Add button Add												

NON-PATENT LITERATURE DOCUMENTS

	Application Number			
NEODIA TION DIOOL COURT	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Filipp	lippo Ramin	
(Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Numb	er	06UVB006	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5
	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Code of USPTO Patent Documents at Iwen USPTO_GDV or MPEP 901.04. 2 Enter office that issued the document, by the In-clearing code (WIPO Standard ST3.). 3 Fee Implanees patent documents, the advantage on the parent of the Emperor unsprinced the seast include of the patent of the patent of the patent of the patent or the Colument by the appropriate symbols as advantaged on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark then if Employin languages the residence is attached.

Application Number | Filing Date | Filing Da

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appropriate selection(s):	
---------------	----------	-------------	------------------------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, not not information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Franco A. Serafini/	Date (YYYY-MM-DD)	2006-09-04			
Name/Print	Franco A. Serafini	Registration Number	52207			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Bast 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.